68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511977-31-01

Enrollment

Registered

2026-04-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

giant cell arteritis - polymyalgia rheumatica spectrum disease

Brief summary

The diagnostic accuracy of 68Ga-FAPI-46 PET/CT in patients with suspected GPSD.

Detailed description

68Ga-FAPI-46 uptake after 28 days of standard treatment in patients with GPSD., 68Ga-FAPI-46 uptake after 6 months of standard treatment in patients with GPSD

Interventions

DRUG[68Ga]FAPI-46

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The diagnostic accuracy of 68Ga-FAPI-46 PET/CT in patients with suspected GPSD.	—

Secondary

Measure	Time frame
68Ga-FAPI-46 uptake after 28 days of standard treatment in patients with GPSD., 68Ga-FAPI-46 uptake after 6 months of standard treatment in patients with GPSD	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 15, 2026